|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Participants with MCI had higher probability of pPD compared to those with normal cognition (<i>p</i> < 0.001).
|
30944240 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
At follow-up (mean follow-up 23.5 ± 10.3 months) 28 (33.3%) of the 84 PD-NC at baseline developed MCI and 4 (4.8%) converted to PDD.
|
30800065 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that hyperinnervation frequencies are significantly higher in the transition between PD without MCI to PDD and that higher burdens of co-existent AD pathology impair this galaninergic response.
|
31454423 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive decline (defined as the incidence of either Parkinson's disease mild cognitive impairment [PD-MCI] or dementia [PDD], diagnosed according to published criteria and blinded to genotype) was studied as the primary outcome.
|
28869277 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
When patients transition from PD-NCI to PD-MCI, there appears to be an increase in functional connectivity in the PCC, suggesting an expansion of the cortical network.
|
29500931 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, high vascular risk was identified as a potential predictor of both MCI and dementia in PD.
|
29572571 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that striatal DAT availability may determine MCI in patients with de novo PD.
|
29526657 |
2018 |
|
Parkinson Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In sum, action appraisal deficits seem to constitute both a hallmark of naturalistic discourse processing in PD and a sensitive subject-level marker for patients with and without MCI.
|
28764852 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PD-MCI group showed deficits across all four categories.
|
28131052 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differentiating MCI from other organic symptoms in PD would facilitate novel therapeutic strategies.
|
28919975 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The conversion rate to dementia was 59.1% in patients with persistent PD-MCI at 1 year vs 7.2% in those with normal cognition during the first year (adjusted odds ratio 16.6, 95% confidence interval 5.1-54.7, <i>p</i> < 0.001).
|
28108638 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study highlights the impact of Parkinson's disease on those providing care when the patient's cognition is poor, including those with MCI.
|
28638598 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> MCI was prevalent in our PD population.
|
29326545 |
2017 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although PD-MCI is a risk factor for developing Parkinson's disease dementia there is evidence to suggest that PD-MCI might consist of distinct subtypes with different pathophysiologies and prognoses.
|
25814509 |
2015 |